Profile data is unavailable for this security.
About the company
Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.
- Revenue in USD (TTM)29.07bn
- Net income in USD5.69bn
- Incorporated1901
- Employees35.00k
- LocationEli Lilly and CoLilly Corporate CtrDrop Code 1094, Lilly Corporate CtrINDIANAPOLIS 46285-0001United StatesUSA
- Phone+1 (317) 276-2000
- Fax+1 (317) 276-3492
- Websitehttps://www.lilly.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Co | 47.14bn | 6.62bn | 149.79bn | 32.20k | 23.31 | 4.59 | 8.75 | 3.18 | 3.01 | 3.01 | 21.49 | 15.27 | 0.4465 | 4.58 | 6.00 | 1,464,099.00 | 6.29 | 2.67 | 7.76 | 3.29 | 79.22 | 74.18 | 14.08 | 6.54 | 1.34 | 5.55 | 0.5629 | 163.84 | 9.09 | 19.01 | 177.58 | 9.43 | -4.35 | 5.22 |
| Merck & Co., Inc. | 57.17bn | 16.64bn | 218.32bn | 68.00k | 13.14 | 5.05 | 10.75 | 3.82 | 6.56 | 6.53 | 22.53 | 17.07 | 0.5781 | 3.03 | 6.54 | 840,720.60 | 16.84 | 7.61 | 21.83 | 10.14 | 70.77 | 70.92 | 29.13 | 16.06 | 1.15 | 21.89 | 0.4223 | 86.06 | 17.31 | 4.12 | 173.18 | 25.79 | 22.48 | 7.49 |
| Pfizer Inc. | 101.13bn | 29.75bn | 245.99bn | 79.00k | 8.45 | 2.81 | 7.07 | 2.43 | 5.19 | 5.11 | 17.62 | 15.59 | 0.5538 | 3.94 | 7.86 | 1,280,152.00 | 16.30 | 6.62 | 21.14 | 8.25 | 62.21 | 74.04 | 29.44 | 21.32 | 1.20 | 22.14 | 0.3153 | 75.72 | 95.16 | 9.00 | 238.05 | 25.51 | 6.28 | 5.39 |
| AbbVie Inc | 57.35bn | 12.57bn | 249.67bn | 50.00k | 19.97 | 17.04 | 11.94 | 4.35 | 7.07 | 7.07 | 32.27 | 8.29 | 0.3939 | 4.95 | 5.42 | 1,146,980.00 | 8.69 | 7.46 | 11.10 | 9.46 | 70.72 | 72.03 | 22.05 | 18.11 | 0.7456 | 8.27 | 0.8324 | 97.89 | 22.69 | 16.99 | 151.71 | 14.13 | 10.44 | 17.93 |
| Eli Lilly And Co | 29.07bn | 5.69bn | 292.18bn | 35.00k | 49.07 | 34.19 | 40.00 | 10.05 | 6.27 | 6.27 | 32.02 | 8.99 | 0.6128 | 1.81 | 4.77 | 830,591.40 | 12.00 | 11.08 | 17.83 | 15.80 | 75.98 | 77.16 | 19.58 | 20.77 | 0.846 | 7.33 | 0.6601 | 53.75 | 15.40 | 5.94 | -9.88 | 15.31 | 11.40 | 10.76 |
| Johnson & Johnson | 95.59bn | 18.37bn | 435.66bn | 141.70k | 24.09 | 5.71 | 17.06 | 4.56 | 6.88 | 6.88 | 35.80 | 29.04 | 0.5398 | 2.85 | 6.16 | 674,580.10 | 10.37 | 9.95 | 13.57 | 12.73 | 67.89 | 66.87 | 19.21 | 19.21 | 1.17 | 123.70 | 0.2992 | 62.33 | 13.55 | 5.46 | 44.85 | 4.77 | 2.51 | 5.87 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2022 | 68.29m | 7.19% |
| PNC Bank, NA (Investment Management)as of 30 Jun 2022 | 52.08m | 5.48% |
| BlackRock Fund Advisorsas of 30 Jun 2022 | 40.19m | 4.23% |
| SSgA Funds Management, Inc.as of 30 Jun 2022 | 33.41m | 3.52% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2022 | 29.57m | 3.11% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2022 | 28.74m | 3.03% |
| PRIMECAP Management Co.as of 30 Jun 2022 | 28.44m | 2.99% |
| Wellington Management Co. LLPas of 30 Jun 2022 | 23.44m | 2.47% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2022 | 20.43m | 2.15% |
| State Farm Investment Management Corp.as of 30 Jun 2022 | 17.41m | 1.83% |
